Literature DB >> 3554244

A common positive trans-acting factor binds to enhancer sequences in the promoters of mouse H-2 and beta 2-microglobulin genes.

A Israël, A Kimura, M Kieran, O Yano, J Kanellopoulos, O Le Bail, P Kourilsky.   

Abstract

Using gel retardation and in vitro "footprinting", we have analyzed the interactions between nuclear proteins derived from various mouse cells and the enhancer and interferon response sequences of the H-2Kb gene. We have found that a protein factor binds a site in the enhancer sequence that partially overlaps the interferon response sequence. This factor also binds to a similar sequence lying in the opposite orientation in the promoter of the mouse beta 2-microglobulin gene, suggesting a common regulatory mechanism. Transfection competition experiments indicate that this factor acts as a positive element in the expression of H-2 and beta 2-microglobulin genes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3554244      PMCID: PMC304716          DOI: 10.1073/pnas.84.9.2653

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  DNAse footprinting: a simple method for the detection of protein-DNA binding specificity.

Authors:  D J Galas; A Schmitz
Journal:  Nucleic Acids Res       Date:  1978-09       Impact factor: 16.971

2.  Absence of reaction of a xenogenic anti-H-2 serum with mouse embryonal carcinoma cells.

Authors:  D Morello; G Gachelin; P Dubois; N Tanigaki; D Pressman; F Jacob
Journal:  Transplantation       Date:  1978-08       Impact factor: 4.939

3.  Absence of significant H-2 and beta 2-microglobulin mRNA expression by mouse embryonal carcinoma cells.

Authors:  D Morello; F Daniel; P Baldacci; Y Cayre; G Gachelin; P Kourilsky
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

4.  Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis.

Authors:  M Fried; D M Crothers
Journal:  Nucleic Acids Res       Date:  1981-12-11       Impact factor: 16.971

5.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

7.  Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells.

Authors:  C M Croce; A Linnenbach; K Huebner; J R Parnes; D H Margulies; E Appella; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

8.  Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon.

Authors:  I Heron; M Hokland; K Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: application to components of the Escherichia coli lactose operon regulatory system.

Authors:  M M Garner; A Revzin
Journal:  Nucleic Acids Res       Date:  1981-07-10       Impact factor: 16.971

10.  The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.

Authors:  F Rosa; H Berissi; J Weissenbach; L Maroteaux; M Fellous; M Revel
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  91 in total

1.  DNA-binding properties of the E1A-associated 300-kilodalton protein.

Authors:  Y Rikitake; E Moran
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  The human cDNA sequence homologous to the mouse MHC class I promoter-binding protein gene contains four additional codons in lymphocytes.

Authors:  C Epplen; J T Epplen
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

3.  Promoter region of HLA-C genes: regulatory elements common to and different from those of HLA-A and HLA-B genes.

Authors:  D Tibensky; T L Delovitch
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

Review 4.  Is TNF involved in the progression of AIDS?

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Virus Genes       Date:  1990-07       Impact factor: 2.332

5.  NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells.

Authors:  J A Molitor; W H Walker; S Doerre; D W Ballard; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  Negative regulation of the major histocompatibility complex class I promoter in embryonal carcinoma cells.

Authors:  J R Flanagan; M Murata; P A Burke; Y Shirayoshi; E Appella; P A Sharp; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

7.  An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes.

Authors:  P H Driggers; D L Ennist; S L Gleason; W H Mak; M S Marks; B Z Levi; J R Flanagan; E Appella; K Ozato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Developmental and tissue-specific expression of the Q5k gene.

Authors:  S Schwemmle; D Bevec; G Brem; M B Urban; P A Baeuerle; E H Weiss
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

9.  The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner.

Authors:  G P Nolan; T Fujita; K Bhatia; C Huppi; H C Liou; M L Scott; D Baltimore
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

10.  Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation.

Authors:  N D Perkins; R M Schmid; C S Duckett; K Leung; N R Rice; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.